期刊
MOVEMENT DISORDERS
卷 25, 期 2, 页码 224-228出版社
WILEY
DOI: 10.1002/mds.22907
关键词
Huntington's disease; uric acid; progression
资金
- NIH, NINDS [NS R01-35284]
- General Clinical Research Centers [RR00052, RR00645, RR00042, RR00044, RR01066, RR07122]
- AstraZeneca
- Vitaline
- National Institutes of Health (NEI, NINDS, NIA)
- Michael J. Fox Foundation
- Medivation
- Neurosearch
- Pfizer
- National Institutes of Health
- Food and Drug Administration
- Spinal Muscular Atrophy Foundation
- Muscular Dystrophy Association
- Boehringer Ingelheim Pharmaceuticals, Inc.
- Neurosearch Sweden AB
- Employment University of Rochester
Uric acid (UA) may be associated with the progression of Parkinson's disease and related neurodegenerative conditions; however, its association with Huntington's disease (HD) progression has not been explored. A secondary analysis of 347 subjects from the CARE-HD clinical trial was performed to examine the relationship between baseline UA levels and the level of functional decline in HD. Outcomes included change in scores at 30 months for the Unified Huntington's Disease Rating Scale components. There was less worsening of total functional capacity over time with increasing baseline UA levels (adjusted mean worsening in scores: 3.17, 2.99, 2.95, 2.28, 2.21, from lowest to highest UA quintile, P = 0.03). These data suggest a possible association between higher UA levels and slower HD progression, particularly as measured by total functional capacity. If confirmed, UA could be an important predictor and potentially modifiable factor affecting the rate of HD progression. (C) 2010 Movement Disorder Society
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据